Dr. Negrin University Hospital, Bco La Ballena s/n, 35010, Las Palmas de Gran Canaria, Las Palmas, Spain.
Dr. Negrin University Hospital, Bco La Ballena s/n, 35010, Las Palmas de Gran Canaria, Las Palmas, Spain; Las Palmas de Gran Canaria University, Juan de Quesada, 30, 35001, Las Palmas de Gran Canaria, Las Palmas, Spain; Fundación Canaria del Instituto Canario de Investigación del Cáncer, Avda de la Trinidad 61 Torre Agustín Arevalo 7 plantaLa Laguna, Santa Cruz de Tenerife, 38204 Spain.
Breast. 2020 Aug;52:45-49. doi: 10.1016/j.breast.2020.04.008. Epub 2020 Apr 22.
Patients with low-risk invasive ductal carcinoma treated with breast-conserving surgery (BCS) were included in a multicatheter brachytherapy APBI protocol. The primary endpoint was ipsilateral breast recurrence. Between December 2008-December 2017, 186 low-risk breast cancer patients were treated with APBI using interstitial multicatheter brachytherapy and followed prospectively. At 5-years of follow-up, cumulative local recurrence (LR) and cause-specific survival was 1.1% (95% CI 0.3-1.9) and 98.3% (95% CI 97.3-99.3%) respectively. No grade 3 adverse effects were observed. Postoperative APBI using multicatheter brachytherapy after BCS in early breast cancer patients have excellent rates of local control and survival, without significant toxicity.
接受保乳手术（BCS）治疗的低危浸润性导管癌患者被纳入多导管近距离放射治疗局部区域推量治疗（APBI）方案。主要终点是同侧乳房复发。2008 年 12 月至 2017 年 12 月，186 例低危乳腺癌患者采用间质多导管近距离放射治疗进行 APBI 治疗，并进行前瞻性随访。在 5 年的随访中，累积局部复发（LR）和无病生存率分别为 1.1%（95%CI0.3-1.9）和 98.3%（95%CI97.3-99.3%）。未观察到 3 级不良事件。早期乳腺癌患者在 BCS 后采用多导管近距离放射治疗进行术后 APBI 治疗，局部控制率和生存率均非常高，且无明显毒性。
